RSS-Feed abonnieren

DOI: 10.1055/a-2404-8089
Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn
Funding This study is sponsored by Janssen Research & Development, LLC. The medical writing support was funded by Janssen Global Services, LLC.
Abstract
Objective
Nipocalimab is a neonatal fragment crystallizable (Fc) receptor (FcRn)—blocking monoclonal antibody that inhibits placental immunoglobulin G (IgG) transfer and lowers circulating maternal IgG levels. In an open-label, single-arm, phase 2 study, nipocalimab demonstrated evidence of safety and efficacy that support further investigation in a pivotal phase 3 trial of recurrent hemolytic disease of the fetus and newborn (HDFN). The phase 3 AZALEA study aims to evaluate the efficacy and safety of nipocalimab in a larger population at risk for severe HDFN, defined as HDFN associated with poor fetal outcomes or neonatal death.
Study Design
AZALEA is a multicenter, randomized, placebo-controlled, double-blind, phase 3 study enrolling alloimmunized pregnant individuals (N ≈ 120) at risk for severe HDFN based on obstetric history. Participants are randomized 2:1 to receive intravenous 45 mg/kg nipocalimab or placebo weekly from 13–16 to 35 weeks gestational age (GA). During the double-blind treatment period, participants receive standard-of-care weekly monitoring for fetal anemia until planned delivery at 37 to 38 weeks of GA. Postnatal follow-up periods are 24 weeks for maternal participants and 104 weeks for neonates/infants.
Results
The primary endpoint is the proportion of pregnancies that do not result in intrauterine transfusion (IUT), hydrops fetalis, or fetal loss/neonatal death from all causes. Key secondary endpoints include the severity of HDFN as measured by a composite HDFN severity index, the earliest time to occurrence of IUT or hydrops fetalis, the modified neonatal mortality and morbidity index in liveborn neonates, and the number of IUTs received. Other endpoints are safety, patient- and caregiver-reported outcomes, pharmacokinetics, pharmacodynamics (e.g., IgG, FcRn receptor occupancy), and immunogenicity of nipocalimab.
Conclusion
AZALEA, the first placebo-controlled, randomized, multicenter, prospective trial in severe HDFN, is designed to evaluate the safety and efficacy of nipocalimab, a potential preventive and noninvasive intervention, in at-risk HDFN pregnancies.
Key Points
-
Severe HDFN leads to poor fetal/neonatal outcomes.
-
IUTs are associated with complications and fetal loss.
-
Nipocalimab blocks IgG recycling and placental transfer.
-
Nipocalimab reduces fetal anemia and IUTs in early-onset severe HDFN.
-
The phase 3 AZALEA study evaluates nipocalimab in severe HDFN.
Keywords
neonatal Fc receptor blocker - nipocalimab - hemolytic disease of the fetus and newborn - HDFN - intrauterine transfusion - red blood cell alloimmunization - safety - efficacy - study designNote
This study is registered with ClinicalTrials.gov Identifier: NCT05912517. EudraCT Number: 2021-002359-12. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05912517 . Date of registration: June 22, 2023.
Publikationsverlauf
Eingereicht: 10. Mai 2024
Angenommen: 22. August 2024
Accepted Manuscript online:
28. August 2024
Artikel online veröffentlicht:
17. September 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang 2015; 109 (02) 99-113
- 2 Mari G, Norton ME, Stone J. et al; Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia–diagnosis and management. Am J Obstet Gynecol 2015; 212 (06) 697-710
- 3 Bhutani VK, Zipursky A, Blencowe H. et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res 2013; 74 (Suppl. 01) 86-100
- 4 Yu D, Ling LE, Krumme AA, Tjoa ML, Moise Jr KJ. Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010. AJOG Glob Rep 2023; 3 (02) 100203
- 5 Brackney K, Labbad G, Hersh A. et al. Missed anti-D immune globulin administration to postpartum patients in 2 health systems: an unrecognized patient safety risk. AJOG Glob Rep 2022; 2 (02) 100038
- 6 Slootweg YM, Zwiers C, Koelewijn JM. et al. Risk factors for RhD immunisation in a high coverage prevention programme of antenatal and postnatal RhIg: a nationwide cohort study. BJOG 2022; 129 (10) 1721-1730
- 7 Bowman J. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43 (12) 1661-1666
- 8 Canlorbe G, Macé G, Cortey A. et al. Management of very early fetal anemia resulting from red-cell alloimmunization before 20 weeks of gestation. Obstet Gynecol 2011; 118 (06) 1323-1329
- 9 Lindenburg ITM, van Kamp IL, van Zwet EW, Middeldorp JM, Klumper FJ, Oepkes D. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation. BJOG 2013; 120 (07) 847-852
- 10 Yinon Y, Visser J, Kelly EN. et al. Early intrauterine transfusion in severe red blood cell alloimmunization. Ultrasound Obstet Gynecol 2010; 36 (05) 601-606
- 11 Zwiers C, Lindenburg ITM, Klumper FJ, de Haas M, Oepkes D, Van Kamp IL. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol 2017; 50 (02) 180-186
- 12 Zwiers C, van Kamp I, Oepkes D, Lopriore E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn - review on current management and outcome. Expert Rev Hematol 2017; 10 (04) 337-344
- 13 Ree IMC, Smits-Wintjens VEHJ, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol 2017; 10 (07) 607-616
- 14 Van't Oever RM, Zwiers C, de Haas M. et al. Severity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: a nationwide retrospective cohort study. BJOG 2024; 131 (06) 769-776
- 15 Zwiers C, van der Bom JG, van Kamp IL. et al. Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol 2018; 219 (03) 291.e1-291.e9
- 16 Tiblad E, Kublickas M, Ajne G. et al. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther 2011; 30 (04) 266-273
- 17 Dean L. Hemolytic disease of the newborn. In: Blood Groups and Red Cell Antigens. Bethesda, MD: National Center for Biotechnology Information; 2005
- 18 Lindenburg IT, Wolterbeek R, Oepkes D, Klumper FJ, Vandenbussche FP, van Kamp IL. Quality control for intravascular intrauterine transfusion using cumulative sum (CUSUM) analysis for the monitoring of individual performance. Fetal Diagn Ther 2011; 29 (04) 307-314
- 19 Mayer B, Hinkson L, Hillebrand W, Henrich W, Salama A. Efficacy of antenatal intravenous immunoglobulin treatment in pregnancies at high risk due to alloimmunization to red blood cells. Transfus Med Hemother 2018; 45 (06) 429-436
- 20 Colpo A, Tison T, Gervasi MT. et al. Personalized treatment with immunoadsorption and intravenous immunoglobulin in a case of severe Rh alloimmunization during pregnancy unresponsive to plasma - exchange. Transfus Apher Sci 2017; 56 (03) 480-483
- 21 Nwogu LC, Moise Jr KJ, Klein KL, Tint H, Castillo B, Bai Y. Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion. Transfusion 2018; 58 (03) 677-684
- 22 Ruma MS, Moise Jr KJ, Kim E. et al. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol 2007; 196 (02) 138.e1-138.e6
- 23 Maisonneuve E, Dugas A, Friszer S. et al. Effect of intravenous immunoglobulins to postpone the gestational age of first intrauterine transfusion in very severe red blood cell alloimmunization: a case-control study. J Gynecol Obstet Hum Reprod 2021; 50 (07) 102119
- 24 Vlachodimitropoulou E, Lo TK, Bambao C. et al. Intravenous immunoglobulin in the management of severe early onset red blood cell alloimmunisation. Br J Haematol 2023; 200 (01) 100-106
- 25 Ling LE, Hillson JL, Tiessen RG. et al. M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther 2019; 105 (04) 1031-1039
- 26 Moise Jr KJ, Oepkes D, Lopriore E, Bredius RGM. Targeting neonatal Fc receptor: potential clinical applications in pregnancy. Ultrasound Obstet Gynecol 2022; 60 (02) 167-175
- 27 Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646
- 28 Roy S, Nanovskaya T, Patrikeeva S. et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model. Am J Obstet Gynecol 2019; 220 (05) 498.e1-498.e9
- 29 Ling LE, Tyler S, Beneduce CJ. et al. Nipocalimab's selective targeting of FcRn and IgG clearance preserves key immune functions (P1–1.Virtual). Neurology 2022; 98 (18 suppl): 1826
- 30 Moise Jr. KJ, Ling LE, Oepkes D. et al. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. N Engl J Med 2024; 8; 391 (06) 526-537
- 31 Momenta Pharmaceuticals. Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results. 2019 . Accessed April 24, 2024 at: https://s24.q4cdn.com/902352448/files/doc_news/archive/be40e644-1eb9-48b1-bf61-b18eb2804487.pdf
- 32 Momenta Pharmaceuticals. Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN. 2020 . Accessed April 24, 2024 at: https://www.globenewswire.com/news-release/2020/07/28/2068533/0/en/Momenta-Pharmaceuticals-Announces-FDA-Rare-Pediatric-Disease-Designation-for-Nipocalimab-in-HDFN.html
- 33 Wesley BD, Sewell CA, Chang CY, Hatfield KP, Nguyen CP. Prescription medications for use in pregnancy-perspective from the US Food and Drug Administration. Am J Obstet Gynecol 2021; 225 (01) 21-32
- 34 Caritis SN, Venkataramanan R. Obstetrical, fetal, and lactation pharmacology–a crisis that can no longer be ignored. Am J Obstet Gynecol 2021; 225 (01) 10-20
- 35 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). 2016 . Accessed March 19, 2024 at: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf
- 36 Antozzi C, Guptill J, Bril V. et al; Vivacity-MG Phase 2 Study Group. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study. Neurology 2024; 102 (02) e207937
- 37 Zhou J, Leu JH, Xiong Y. et al. 232 Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN. Am J Obstet Gynecol 2024; 230 (01 suppl): S138
- 38 Hutcheon JA, Platt RW, Abrams B, Himes KP, Simhan HN, Bodnar LM. A weight-gain-for-gestational-age z score chart for the assessment of maternal weight gain in pregnancy. Am J Clin Nutr 2013; 97 (05) 1062-1067
- 39 Velkova E. Correlation between the amount of anti-D antibodies and IgG subclasses with severity of haemolytic disease of foetus and newborn. Open Access Maced J Med Sci 2015; 3 (02) 293-297
- 40 Oepkes D, van Kamp IL, Simon MJ, Mesman J, Overbeeke MA, Kanhai HH. Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstet Gynecol 2001; 184 (05) 1015-1020
- 41 Gudlaugsson B, Hjartardottir H, Svansdottir G. et al. Rhesus D alloimmunization in pregnancy from 1996 to 2015 in Iceland: a nation-wide population study prior to routine antenatal anti-D prophylaxis. Transfusion 2020; 60 (01) 175-183
- 42 Royal College of Obstetricians & Gynaecologists. The Management of Women with Red Cell Antibodies during Pregnancy (Green-top Guideline No. 65). May 2014. Accessed March 16, 2023 at: https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/the-management-of-women-with-red-cell-antibodies-during-pregnancy-green-top-guideline-no-65/
- 43 Slootweg YM, Lindenburg IT, Koelewijn JM, Van Kamp IL, Oepkes D, De Haas M. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol 2018; 219 (04) 393.e1-393.e8
- 44 Leu JH, Vermeulen A, Abbes C, Arroyo S, Denney WS, Ling LE. Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study. Front Neurosci 2024; 18: 1302714
- 45 Taylor P, Schett G, Ibrahim F. et al. Efficacy and safety of nipocalimab in patients with moderate to severe active rheumatoid arthritis (RA): the multicenter, randomized, double-blinded, placebo-controlled phase 2a IRIS-RA study. Arthritis Rheumatol 2023;75(suppl 9). Accessed April 24, 2024 at: https://acrabstracts.org/abstract/efficacy-and-safety-of-nipocalimab-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-ra-the-multicenter-randomized-double-blinded-placebo-controlled-phase-2a-iris-ra-study/
- 46 Panchakshari R, Loza M, Huizinga T. et al. Pharmacodynamic effects of nipocalimab in patients with moderate to severe active rheumatoid arthritis (RA): results from the multicenter, randomized, double-blinded, placebo-controlled phase 2A IRIS-RA study. Arthritis Rheumatol 2023;75(suppl 9). Accessed April 24, 2024 at: https://acrabstracts.org/abstract/pharmacodynamic-effects-of-nipocalimab-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-ra-results-from-the-multicenter-randomized-double-blinded-placebo-controlled-phase-2a-iris/
- 47 Guptill JT, Sleasman JW, Steeland S. et al. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis. Autoimmunity 2022; 55 (08) 620-631